THE ANALYSIS OF NEW DRUG REIMBURSEMENT DECISION MAKING IN SOUTH KOREA AFTER THE INTRODUCTION OF POSITIVE LISTING SYSTEM
Author(s)
Kim S1, Cho H1, Yoo H2, Cho J3, Kang K4, Kim J5
1Novartis Korea, Seoul, Korea, Republic of (South), 2AstraZeneca Korea, Seoul, Korea, Republic of (South), 3Lilly Korea, Seoul, Korea, Republic of (South), 4Abbvie Korea, Seoul, Korea, Republic of (South), 5Ipsen Korea, Seoul, Korea, Republic of (South)
OBJECTIVES: In 2006, the Positive Listing System (PLS) was introduced to select effective drugs in terms of clinical and economic aspects for the national health insurance in Korea. The aim of this study was to review the new drugs’ listing rates and the time to patient access of new drugs after the PLS. Also, we aimed to analyze if the pricing system alteration after the PLS had any effect on the time to patient access. METHODS: All drugs evaluated by Drug Reimbursement Evaluation Committee under HIRA from July 2007 to December 2016 were included in the analysis. Based on disclosed reports, the characteristics of the drugs, listing rates and the time to patient access were analyzed. RESULTS: The total number of drugs was 307, of which the number of listed and non-listed drugs were 247 (80.5%) and 60 (19.5%). The overall listing rate was 80.5%, whereas the listing rate within 2 years from market authorization was 61.2%. Out of the total 44 oncology drugs, the listing rates were 65.9% overall and 31.8% within 2 years, and 71.9% and 48.4% in orphan drugs (n=64), respectively. The median time to patient access was 16.1 months in total drugs, 30.5 months in oncology drugs, 23.5 months in orphan drugs. Finally, the time to patient access for the drugs under the pricing system alteration after the PLS was 12.1 months, which depicted a drastic improvement when compared to the drugs before the alteration (17.1 months). CONCLUSIONS: In South Korea, the time to patient access was much longer compared to European or any other Asian countries. However, the patients’ enhanced accessibility by the alteration of pricing system had a definite improved outcome on oncology and orphan drugs. Therefore, the government is required to improve the drug reimbursement system by performing constant analysis on patients’ accessibility.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PHP138
Topic
Health Policy & Regulatory
Topic Subcategory
Reimbursement & Access Policy
Disease
Multiple Diseases